NP

Nagamani Puppala

Active Director Whole-Time Director DIN 10125814
DIN 10125814 First appointment Apr 2023 Primary industry Pharma
Unlock full profile Investments Β· shareholding Β· contact details
Current companies 1 active board seats
Total affiliations 1 Since Apr 2023
Shareholding value β€’β€’β€’β€’ Premium profile

About Nagamani Puppala

Data last updated:

Nagamani Puppala is a Whole-Time Director at Q'ras Pharmaceuticals Private Limited (since 2023). The company operates in Pharma.

DIN 10125814
Primary Designation Whole-Time Director
Industry Pharma
First Appointment 29 Apr 2023
Oldest Company Age 3 yrs

Current companies

CompanyDesignationAppointmentFoundedRevenueStatus
Whole-Time Director29 Apr 20232023Active

Board colleagues of Nagamani Puppala

Directorship timeline

Open interactive timeline →
Q'ras Pharmaceuticals Private Limited
Premium access

Shareholding and investment profile for Nagamani Puppala

Company-level share counts, filed values, and quarterly changes require authenticated premium access.

  • Company-level holdings
  • Filed share counts
  • Reported values
  • Quarterly changes
Unlock shareholding

Verified entity values are shown only after access is granted.

Frequently Asked Questions about Nagamani Puppala

Nagamani Puppala currently holds 1 directorship: Q'ras Pharmaceuticals Private Limited (Whole-Time Director, since 29 Apr 2023).

Nagamani Puppala was first appointed on 29 Apr 2023 as Whole-Time Director at Q'ras Pharmaceuticals Private Limited.

The current boards of Nagamani Puppala's companies include Rajesh Kondadadi (Q'ras Pharmaceuticals Private Limited), Somuri Rohith Hari Kishore (Q'ras Pharmaceuticals Private Limited), Swathi Kendyala (Q'ras Pharmaceuticals Private Limited), Uma Rani Somuri (Q'ras Pharmaceuticals Private Limited).

Explore millions of companies β€” effortlessly

Access structured, verified intelligence on 7M+ companies across industries, sectors, and global markets. From early-stage startups to large enterprises, discover ownership, leadership, funding, financials, acquisitions, and market signals β€” all in one powerful platform.

Free account with essential features Instant access to company reports Enterprise solutions available